The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


AMYViD



Eli Lilly Nederland B.V.EU/1/12/805/001-002

Main Information

Trade NameAMYViD
Active SubstancesFlorbetapir (18f)
Dosage FormSolution for injection
Licence HolderEli Lilly Nederland B.V.
Licence NumberEU/1/12/805/001-002

Group Information

ATC CodeV09AX Other central nervous system diagnostic radiopharmaceuticals
V09AX05 florbetapir (18F)

Status

License statusAuthorised
Licence Issued14/01/2013
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
Marketing Status

Documents

Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back